Defective blood dendritic cells in chronic myeloid leukemia correlate with high plasmatic VEGF and are not normalized by imatinib mesylate (Q45041464)

8 December 2017

title

Defective blood dendritic cells in chronic myeloid leukemia correlate with high plasmatic VEGF and are not normalized by imatinib mesylate (English)

1 reference

8 December 2017

main subject

chronic myeloid leukemia

0 references

1 reference

1 reference

1 reference

1 reference

8 December 2017

Boissel N

1 reference

8 December 2017

Rousselot P

1 reference

8 December 2017

Raffoux E

1 reference

8 December 2017

Cayuela JM

1 reference

8 December 2017

Maarek O

1 reference

8 December 2017

Charron D

1 reference

8 December 2017

Degos L

1 reference

8 December 2017

Dombret H

1 reference

8 December 2017

Rea D

1 reference

8 December 2017

language of work or name

1 reference

1 October 2004

1 reference

8 December 2017

1 reference

8 December 2017

1 reference

8 December 2017

1 reference

8 December 2017

page(s)

1656-1661

1 reference

Interferon-alfa for chronic myeloid leukemia

8 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403474

Allogeneic stem cell transplantation for chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403474

Interferon-alpha, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403474

BDCA-2, BDCA-3, and BDCA-4: three markers for distinct subsets of dendritic cells in human peripheral blood

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403474

Plasmacytoid dendritic cells: from specific surface markers to specific cellular functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403474

VEGF165 mediates formation of complexes containing VEGFR-2 and neuropilin-1 that enhance VEGF165-receptor binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403474

Tumour escape from immune surveillance through dendritic cell inactivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403474

Imatinib mesylate (STI571) decreases the vascular endothelial growth factor plasma concentration in patients with chronic myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403474

Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403474

The Id proteins and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403474

Id2 and Id3 inhibit development of CD34(+) stem cells into predendritic cell (pre-DC)2 but not into pre-DC1. Evidence for a lymphoid origin of pre-DC2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403474

The p38 MAPK pathway mediates the growth inhibitory effects of interferon-alpha in BCR-ABL-expressing cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403474

Identification of dendritic cell colony-forming units among normal human CD34+ bone marrow progenitors that are expanded by c-kit-ligand and yield pure dendritic cell colonies in the presence of granulocyte/macrophage colony-stimulating factor and t

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403474

Inhibitory effect of imatinib on normal progenitor cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403474

Imatinib mesylate affects the development and function of dendritic cells generated from CD34+ peripheral blood progenitor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403474

Imatinib mesylate impairs Flt3L-mediated dendritic cell expansion and antitumor effects in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403474

Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403474

Plasmacytoid dendritic cells prime IFN-γ-secreting melanoma-specific CD8 lymphocytes and are found in primary melanoma lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403474

Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403474

7 January 2021

A neuronal receptor, neuropilin-1, is essential for the initiation of the primary immune response

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403474

7 January 2021

Prognostic significance of cellular vascular endothelial growth factor expression in chronic phase chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403474

7 January 2021

Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403474

7 January 2021

Circulating blood dendritic cells from myeloid leukemia patients display quantitative and cytogenetic abnormalities as well as functional impairment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403474

7 January 2021

Sézary syndrome patients demonstrate a defect in dendritic cell populations: effects of CD40 ligand and treatment with GM-CSF on dendritic cell numbers and the production of cytokines

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403474

7 January 2021

Identifiers

DOI

10.1038/SJ.LEU.2403474

1 reference

Dimensions Publication ID

8 December 2017

1032969136

0 references

1 reference